Biocon Limited (BIOCON NSE) stock market data APIs
INR378.3895
-5.64(-1.5%)
as of July 4, 2025
Try our APIs with
free plan!
Biocon Limited Financial Data Overview
Price chart is built with
Anychart
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Prev. Close
378.3895
Open
372.7506
High
383.6897
Low
370.3522
52 wk Range
290.6115-404.1596
Market Cap
507 196 M
P/E Ratio
44.9232
Shares Outstanding
1 335 M
Revenue
152 617 M
EPS
2.71
Dividends (Yield)
0.0014
Beta
0.219
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biocon Limited data using free add-ons & libraries
Get Biocon Limited Fundamental Data
Biocon Limited Fundamental data includes:
- Net Revenue: 152 617 M
- EBITDA: 31 239 M
- Earnings Per Share: 8
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: 1.43
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biocon Limited News
New
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis
(Graphic: Business Wire) Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo It...
Biocon Ltd (BOM:532523) Q3 2025 Earnings Call Highlights: Strong Biosimilars Growth Amidst ...
Revenue from Operations: INR3,821 crore, up 10% year-on-year and 6% sequentially on a like-for-like basis. Total Group Revenue: INR3,856 crore, a growth of 7% year-on-year and 6% sequentially. Group C...
India's Biocon plans IPO for biosimilars business by March 2026
By Rishika Sadam HYDERABAD (Reuters) -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its...
Biocon's Q3 revenue dips; banks on obesity drugs for future growth
HYDERABAD (Reuters) - Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
